< Terug naar vorige pagina
Onderzoeker
Christophe Pannecouque
- Disciplines:Microbiologie, Systeembiologie, Laboratoriumgeneeskunde
Affiliaties
- Laboratorium Virologie en Chemotherapie (Rega Instituut) (Afdeling)
Lid
Vanaf1 jul 2002 → Heden
Projecten
1 - 3 of 3
- Geautomatiseerd platform voor het verzamelen van gegevens over multiparameter levende ziekteverwekkers met een hoger of onbekend risico wat betreft bioveiligheidVanaf26 jun 2014 → 31 dec 2018Financiering: Hercules - Zware apparatuur
- Mechanistische studie van virus entry en replicatie. Een fundamentele benadering voor de ontwikkeling van nieuwe en specifieke antivirale chemotherapeutica.Vanaf1 jan 2010 → 31 dec 2014Financiering: BOF - Geconcert. Onderzoeksacties vanaf 1994
- Identificatie van biomerkers en nieuwe therapeutische doelwitten in HTLV-1-geassocieerde pathologieën.Vanaf1 jan 2010 → 31 dec 2013Financiering: FWO Onderzoeksproject
Publicaties
21 - 30 van 399
- Structure-directed linker optimization of novel HEPTs as non-nucleoside inhibitors of HIV-1 reverse transcriptase(2023)
Auteurs: Christophe Pannecouque, Erik De Clercq
- Anti-SARS-CoV-2 Activity and Cytotoxicity of Amaryllidaceae Alkaloids from Hymenocallis littoralis(2023)
Auteurs: Steven De Jonghe, Johan Neyts, Christophe Pannecouque
- Development of fluorine-substituted NH2- biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability(2023)
Auteurs: Christophe Pannecouque, Erik De Clercq
Pagina's: 1192 - 1203 - From design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interface(2023)
Auteurs: Erik De Clercq, Christophe Pannecouque
- Hybrids of delavirdine and piperdin-4-yl-aminopyrimidines (DPAPYs) as potent HIV-1 NNRTIs: Design, synthesis and biological activities(2023)
Auteurs: Christophe Pannecouque
- Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket(2023)
Auteurs: Erik De Clercq, Christophe Pannecouque
Pagina's: 2102 - 2115 - Identification of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase(2023)
Auteurs: Erik De Clercq, Christophe Pannecouque
- Development of novel S-N3-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity(2023)
Auteurs: Christophe Pannecouque, Erik De Clercq
- Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs(2023)
Auteurs: Christophe Pannecouque, Erik De Clercq
- Disubstituted pyrimidine-5-carboxamide derivatives as novel HIV-1 NNRTIs: Crystallographic overlay-based molecular design, synthesis, and biological evaluation(2023)
Auteurs: Erik De Clercq, Christophe Pannecouque
Patenten
1 - 7 van 7
- Antiviral activity of bicyclic heterocycles (Inventor)
- Antiviral activity of novel bicyclic heterocycles (Inventor)
- Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- Antiviral activity of bicyclic heterocycles (Inventor)
- Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION (Inventor)